Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.

[BACKGROUND] Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment.

[AIMS] This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions.

[METHODS] HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) in a prospective, multicenter observational study on rituximab safety across Italian hematology units (March 2018-June 2022).

[RESULTS] Of 772 patients with Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL), 412 (62.6%) completed the HRQoL assessment. Overall, patients reported acceptable quality of life. Key concerns included reduced enjoyment of life (45.1%), poor sleep (42.0%), and dissatisfaction with quality of life (41.0%). Functional impairments and emotional distress were also reported. CLL patients showed slightly better physical and lymphoma-specific well-being than NHL patients. Patients with other hematologic diseases had lower scores across several domains.

[CONCLUSIONS] While HRQoL is generally acceptable in NHL and CLL, functional well-being is most impacted. Routine integration of HRQoL assessments is essential to identify unmet needs and support patient-centered care.